<DOC>
	<DOCNO>NCT00046774</DOCNO>
	<brief_summary>This study examine safety effect monoclonal antibody MRA patient systemic lupus erythematosus ( SLE ) . Antibodies normally fight invade organism . In autoimmune disease , lupus , however , antibody attack body tissue . MRA antibody manufacture laboratory block action interleukin-6 ( IL-6 ) , substance increase antibody production involve inflammation may cause organ damage SLE . Patients 18 year age older moderately active systemic lupus erythematosus may eligible 6-month study . Candidates screen blood urine test , chest X-ray , electrocardiogram ( EKG ) , screen test certain cancer . Participants receive total seven infusion MRA give every 2 week clinic . The MRA infuse period 1 hour catheter ( thin plastic tube ) insert arm vein . Patients observe 1 2 hour infusion drug side effect . For first last infusion , patient return clinic blood test 24 48 hour infusion . Additional test may do medically indicate . Three different dos MRA use three group patient . The first group ( 4 patient ) receive low dose . If dose well tolerate , second group ( 6 patient ) receive high dose . If dose also well tolerate , third group ( 6 patient ) receive high study dose . Patients evaluate various interval 3 month last dose MRA . The follow-up visit include review patient medical history , physical examination , blood urine test , EKG .</brief_summary>
	<brief_title>Monoclonal Antibody Treatment Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Interleukin-6 ( IL-6 ) level elevate human murine systemic lupus erythematosus ( SLE ) . Blocking action IL-6 ameliorate disease activity murine model SLE . MRA humanize monoclonal antibody human IL-6 receptor . Data clinical trial patient rheumatoid arthritis suggest MRA may safe agent block effect IL-6 therefore may use evaluate effect IL-6 blockade patient SLE . In open label , dose-escalating , Phase I study , 27 subject moderately active SLE may enrol . Subjects treat bi-weekly infusion one three dos ( 2mg/kg , 4 mg/kg 8 mg/kg ) MRA 12 week follow 8 week last dose . Patients without lupus nephritis may enrol require immediate immunosuppressive therapy prednisone dose less equal 0.3 mg/kg/day . Safety evaluate use standard clinical laboratory parameter . To assess potential effect MRA SLE , clinical laboratory evaluation surrogate marker inflammation disease activity , autoantibody production lymphocyte subset , compare treatment . Patients either tolerate drug clinically significant increase disease activity respond moderate dos corticosteroid withdraw protocol . If regimen show well tolerate , study efficacy plan . This agent expect devoid common toxicity therapy commonly use treatment SLE , myelosuppression , amenorrhea osteoporosis . This study provide important preliminary information safety possible effect IL-6 blockade SLE patient , intervention successful animal model yet study human .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>IINCLUSION CRITERIA : Age entry least 18 year Must give write informed consent prior entry protocol Must fulfill least 4 follow criterion SLE define American College Rheumatology : Malar rash . Fixed Erythema , flat raise , malar eminence . Discoid rash . Erythematous raise patch adherent keratotic scaling follicular plugging ; atrophic scarring may occur . Photosensitivity . Exposure UV light cause rash . Oral Ulcers . Includes oral nasopharyngeal , observed physician . Arthritis . Nonerosive arthritis involve two peripheral joint , characterize tenderness , swell effusion . Serositis . Pleuritis pericarditis document ECG rub evidence pericardial effusion . Renal disorder . Proteinuria great 0.5 g/d great 3+ , cellular cast . Neurologic disorder . Seizures without cause psychosis without cause . Hematologic disorder . Hemolytic anemia leukopenia ( le 4000/microL ) lymphopenia ( le 1500/microL ) thrombocytopenia ( le 100,000/microL ) absence offend drug . Immunologic disorder . AntidsDNA , antiSm , and/or antiphospholipid . Antinuclear antibody . An abnormal titer ANAs immunofluorescence equivalent assay point time absence drug know induce ANAs . Moderately active lupus require immediate immunosuppressive therapy oral prednisone less equal 0.3 mg/kg/day ( equivalent ) . Moderately active lupus define either two ( b ) set criterion : . Chronic glomerulonephritis inadequate response least 6 month adequate immunosuppressive therapy ( pulse methylprednisolone , cyclophosphamide , azathioprine , cyclosporine , mycophenolate mofetil high dose daily corticosteroid , MTX IV Ig ) , i. less 30 % increase creatinine compare low level treatment , ii . proteinuria less equal 1.5 time baseline treatment , iii . le equal 2+ cellular cast urinary sediment ( scale 04 ) , iv . Extrarenal disease activity exceed 10 nonrenal component SELENASLEDAI score . b . Patients moderately active extrarenal lupus define extrarenal SELENASLEDAI score range 3 10 , inclusive . The SELENASLEDAI score stable least two week prior screen . One following : ) Serum dsDNA level great equal 30 IU ii ) IgG anticardiolipin antibody level great equal 20 GPL iii ) CRP great 0.8 mg/dL iv ) ESR great 25 mm/hr men ; ESR great 42 mm/hr woman . Stable dose prednisone less equal 0.3 mg/kg/day ( equivalent ) least 2 week first treatment . EXCLUSION CRITERIA : Pregnant lactate woman . Women childbearing potential require negative pregnancy test screening . Women childbearing potential fertile men practice unwilling practice birth control period three month completion study Any therapy human murine antibody experimental therapy within 3 month Therapy cyclophosphamide ; pulse methylprednisolone IV Ig within 4 week ; azathioprine , mycophenolate mofetil , cyclosporine methotrexate within 2 week first study treatment Initiation change dose ACEinhibitor within 2 week first study treatment Allergy murine human antibody History anaphylaxis Serum creatinine great 3.0 mg/dL Active severe CNS lupus ( encephalopathy , cerebrovascular accident , transverse myelitis , severe depression , psychosis ) Previous history ischemic heart disease evidence ischemic heart disease ECG Congestive heart failure cardiomyopathy History thrombosis recurrent 2nd trimester abortion ( 3 ) elevate level anticardiolipin antibody lupus anticoagulant unless patient anticoagulation History malignancy exception basal cell squamous cell carcinoma skin situ carcinoma cervix within last 3 year Active infection require use intravenous antibiotic resolve within 1 week Day 1 Any active viral infection resolve within 10 day prior Day 1 History reactivation EB viral infection great 1,000 EBV genome equivalent/10 ( 6 ) cell PBMC preparation Active hepatitis B , hepatitis C HIV infection WBC le 3500/microL ANC less 3000/microL Hgb less 8.0 g/dL platelet le 50,000/microL absolute lymphocyte count less equal 500/microL . ALT and/or AST great 2 time upper limit normal ( ULN ) alkaline phosphatase great 1.5 time ULN Significant concurrent medical condition , opinion principal investigator , could affect patient 's ability tolerate complete study Live vaccine within 4 week first infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 13, 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Nephritis</keyword>
	<keyword>Biologic Therapy</keyword>
	<keyword>Lymphocytes</keyword>
	<keyword>Response</keyword>
	<keyword>Lupus</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>SLE</keyword>
</DOC>